炎症因子IL-32、凋亡因子Apaf-1和胃癌

摘要/Abstract

中图分类号:

R735.2

李佳欣, 齐洁敏. 炎症因子IL-32、凋亡因子Apaf-1和胃癌[J]. 承德医学院学报, 2020, 37(3): 247-250.

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] 郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2019,41(1):19-28.
[3] Dahl CA, Schall RP, He HL, et al.Identification of a novel gene expressed in activated natural killer cells and T cells[J]. J Immunol, 1992, 148(2): 597-603.
[4] Kim SH, Han SY, Azam T, et al.Interleukin-32: a cytokine and inducer of TNFalpha[J]. Immunity, 2005, 22(1): 131-142.
[5] Kang JW, Park YS, Lee DH, et al.Interaction network mapping among IL-32 isoforms[J]. Biochimie, 2014, 101: 248-251
[6] Ishigami S, Arigami T, Uchikado Y, et al.IL-32 expression is an independent prognostic marker for gastric cancer[J]. Med Oncol, 2013, 30(2): 472.
[7] Gasparini C, Celeghini C, Monasta L, et al.NF-κB pathways in hematological malignancies[J]. Cell Mol Life Sci, 2014, 71(11): 2083-2102.
[8] Lee H, Herrmann A, Deng JH, Jie-Hui Deng, et al.Persistently Activated Stat 3 Maintains Constitutive NF-κB Activity in Tumors[J]. Cancer Cell, 2009, 15(4): 283-293.
[9] Shostak K, Chariot A.EGFR and NF-κB: partners in cancer[J]. Trends Mol Med, 2015, 21(6): 385-393.
[10] Korniluk A, Koper O, Kemona H, et al.From inflammation to cancer[J]. Ir J Med Sci, 2017, 186(1): 57-62.
[11] Pavlovic M, Gajovic N, Jurisevic M, et al.Diverse Expression of IL-32 in Diffuse and Intestinal Types of Gastric Cancer[J]. Gastroenterol Res Pract, 2018: 6578273.
[12] Khawar MB, Abbasi MH, Sheikh N.IL-32: A Novel Pluripotent Inflammatory Interleukin, Towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis[J]. Mediators Inflamm, 2016: 8413768.
[13] Tsai CY, Wang CS, Tsai MM, et al.Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis[J]. Clin Cancer Res, 2014, 20(9): 2276-2288.
[14] 杜三军,李多,于永强,等. 胃癌患者血清IL-32、TNF-α表达意义研究[J]. 中国预防医学杂志,2018,19(12): 933-936.
[15] Erturk K, Tastekin D, Serilmez M, et al.Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer[J]. Tumour Biol, 2016, 37(1): 405-412.
[16] Zeng Q, Li S, Li, Zhou Y, et al.Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression[J]. Cytokine, 2014, 65(1): 24-32.
[17] Nishida A, Andoh A, Inatomi O, et al.Interleukin-32 expression in the pancreas[J]. J Biol Chem, 2009, 284(26): 17868-17876.
[18] Yang Yi, Wang Zihao, Zhou Yiming, et al.Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis[J]. World J Surg Oncol, 2015, 13: 146.
[19] Sloot YJE, Rabold K, Ulas T, et al.Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration[J]. Cell Oncol(dordr), 2019, 42(5): 691-703.
[20] Nicholl MB, Chen X, Qin C, et al.IL-32α has differential effects on proliferation and apoptosis of human melanoma cell lines[J]. J Surg Oncol, 2016, 113(4): 364-369.
[21] Zou H, Henzel WJ, Liu X, et al.Apaf-1, a human protein homologous to C.elegans CED-4, participates in cytochrome c-dependent activation of caspase-3[J]. Cell, 1997, 90(3): 405-413.
[22] Cain K, Bratton SB, Cohen GM.The Apaf-1 apoptosome: a large caspase-activating complex[J]. Biochimie, 2002, 84(2-3): 203-214.
[23] Qi Hu, Di Wu, Wen Chen, et al.Molecular determinants of caspase-9 activation by the Apaf-1 apoptosome[J]. Proc Natl Acad Sci USA, 2014, 111(46): 16254-16261.
[24] Kantari C, Walczak H.Caspase-8 and bid: caught in the act between death receptors and mitochondria[J]. Biochim Biophys Acta, 2011, 1813(4): 558-563.
[25] Shakeri R, Kheirollahi A, Davoodi J.Apaf-1: Regulation and function in cell death[J]. Biochimie, 2017, 135: 111-125.
[26] Crowley LC, Waterhouse NJ.Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow Cytometry[J]. Cold Spring Harb Protoc, 2016, 2016(11). doi: 10.1101/pdb.prot087312.
[27] Wang HL, Bai H, Li Y, et al.Rationales for expression and altered expression of apoptotic protease activating factor-1 gene in gastric cancer[J]. World J Gastroenterol, 2007, 13(38): 5060-5064.
[28] 殷舞,莫祥兰,韦海明,等. Survivin、Apaf-1和caspase-9在胃癌腹膜转移中的表达及意义[J]. 广东医学,2014,35(2): 221-223.
[29] Han R, Chen XY.Apoptotic protease activating factor-1 negatively regulates Wnt signaling in hepatocellular carcinoma[J]. Kaohsiung J Med Sci, 2019, 35(8): 459-466.
[30] Abdelrahman AE, Fathy A, Elsebai EA, et al.Prognostic impact of Apaf-1,Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy[J]. Ann Diagn Pathol, 2018, 35: 27-37.
[31] Hong JT, Son DJ, Lee CK, et al.Interleukin 32, inflammation and cancer[J]. Pharmacol Ther, 2017, 174: 127-137.

炎症因子IL-32、凋亡因子Apaf-1和胃癌

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

[1]	柏友兰, 刘明伟, 王小杰, 李欣. 膜联蛋白A7低表达对人胃癌MGC-803细胞迁移和侵袭的影响[J]. 承德医学院学报, 2021, 38(5): 374-378.
[2]	李美川, 刘明伟, 赵依纳, 王小杰, 李欣. LncRNA TCONS_00022381在胃癌组织中的表达及其对胃癌SGC-7901细胞增殖的影响[J]. 承德医学院学报, 2021, 38(2): 96-99.
[3]	苑双蕊, 杨岳云, 李春阳, 刘晟宇, 宋佳, 曹振东. 胃癌术前T分期影像学研究进展[J]. 承德医学院学报, 2021, 38(2): 152-156.
[4]	刘欢, 刘莎莎, 申兴斌. Cx43和mTOR/p70S6K信号通路在胃癌中的研究进展[J]. 承德医学院学报, 2021, 38(1): 60-63.
[5]	杨爱峰, 侯鹏飞. miR-145-5p靶向MEST抑制胃癌上皮细胞增殖侵袭转移的研究[J]. 承德医学院学报, 2020, 37(6): 451-455.
[6]	刘长兵, 姚丰, 牛多山, 张佐阳. 胃癌组织中ZMYND8蛋白的表达及临床病理学意义[J]. 承德医学院学报, 2020, 37(4): 271-274.
[7]	朱海峰, 李峰. 甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析[J]. 承德医学院学报, 2019, 36(5): 383-387.
[8]	赵依纳, 王小杰, 吴雪艳, 代雅蕊, 张佳璐, 李欣. 敲低膜联蛋白A5对人胃癌细胞Galectin-3表达的影响^*[J]. 承德医学院学报, 2019, 36(1): 4-7.
[9]	林晓伟. 替吉奥联合奥沙利铂对晚期胃癌患者疾病控制及毒副反应的影响[J]. 承德医学院学报, 2018, 35(5): 390-392.
[10]	陈小茶, 甄结清, 陈艳红. 快速康复护理在胃癌围手术期护理中的应用[J]. 承德医学院学报, 2018, 35(4): 326-328.
[11]	李亚敏, 薛绍鸥, 张雷. 胃癌患者癌因性疲乏研究进展[J]. 承德医学院学报, 2018, 35(2): 160-162.